Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST